Pancreatic Cancer Action

PCE is pleased to announce our latest position paper addressing the critical issue of pancreatic cancer across Europe in light of the 2024 EU Elections. Developed collaboratively by Pancreatic Cancer…   …Read More »Position Paper on Pancreatic Cancer Across Europe in Light of the 2024 EU Elections

The results of a large pan-European study by the European Study Group for Pancreatic Cancer (ESPAC) involving 732 patients has shown that the combination of gemcitabine plus capecitabine adjuvant therapy  ...Read More »Two-drug combination improves survival for operable pancreatic cancer

We have seen a lot in the press recently about the advances in immunotherapy for many cancers and, in the case of melanoma, with extraordinary results. We’ve not as yet  ...Read More »Have we now found a way for immunotherapy to work in pancreatic cancer too?